Efficacy and Safety of Chinese Herbal Medicine on Ovarian Cancer After Reduction Surgery and Adjuvant Chemotherapy: A Systematic Review and Meta-Analysis

Background: Ovarian cancer (OvC) is a malignant tumor invade ovarian epithelium and interstitium. Reduction surgery combined with adjuvant chemotherapy is standard treatment for OvC patients, but adverse effects due to chemotherapy still remain a major problem. While Chinese herbal medicine (CHM) therapy has an unique therapeutic effect to reduce side effects of chemotherapy by boosting immune system, but the evidence of CHM to treat these OvC patients are limited. Objective: We conducted systematic review to evaluate the efficacy and safety of CHM in the treatment of OvC after reduction surgery and adjuvant chemotherapy. Method: Chinese National Knowledge Infrastructure (CNKI) and PubMed up to Dec 31st 2018 were searched to identify relevant studies. Only randomized controlled trials (RCTs) were included, there was no limitation on language of the publications. Data were extracted from all included studies and meta-analysis was performed with Review Manager 5.3. Study quality was assessed and pooled risk ratios (RR) or mean difference (MD) with 95% CIs were used to evaluate the efficacy and safety of CHM. Results: A total of 18 RCTs involving 975 participants were included. There were no placebo, no treatment and CHM alone. Compared with Western Medicine (WM) alone, CHM combined with WM (CHM-WM) significantly improved TCM syndromes and symptoms, KPS scores, CD4 counts, CA125 levels, and three-year survival rate (P
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

The AVANOVA2 trial enrolled a total of 97 patients with high-grade serous or endometrioid platinum-sensitive recurrent ovarian cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Authors: Rezaeian M, Sedaghatkish A, Soltani M Abstract Although intraperitoneal chemotherapy (IPC) has been suggested as a promising method for the management of peritoneal dissemination (PD) of ovarian or colorectal cancers, the actual clinical use of this method has been restricted due to such problems as poor drug penetration into the tumor and high side effects. It is, therefore, necessary to develop new strategies to improve the efficacy of this approach. In the present work, a new strategy is proposed based on intraperitoneal (IP) injection of thermosensitive liposomal doxorubicin (TSL-Dox) with triggered re...
Source: Drug Delivery - Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research
This study aimed to elucidate impact of age on the clinicopathologic characteristics and survival of epithelial ovarian neoplasms in the reproductive age.MethodsThe clinical records of patients diagnosed as epithelial ovarian cancer or epithelial borderline ovarian tumor at the age of 40  years or younger at multiple institutions in the Tokai Ovarian Tumor Study Group were reviewed retrospectively. All patients were stratified into two age groups: group A (≤ 30 years) and group B (31–40 years). Univariate and multivariate analyses were performed to evaluate overall survival and disease-free sur...
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
AbstractFirst-line chemotherapy for many solid tumors is limited by toxicity. There is a growing interest in maintenance therapy as a strategy for prolonging the benefits of first-line therapy while minimizing toxicity. Maintenance therapy can comprise either continuation of an agent given as part of the first-line regimen (continuation maintenance) or treatment with a new agent (switch maintenance). Maintenance therapy is already established in several solid tumors, including lung, breast, gastric, colorectal, and ovarian cancer. Immune checkpoint inhibitor treatment has been shown to prolong duration of response and over...
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   FIGO Grade 1 Endometrial Endometrioid Adenocarcinom a;   FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma;   FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Gra...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
We report the case of a 87-year-old and -frailty woman with advanced ovarian cancer, not eligible for surgery or standard first-line intravenous chemotherapy. The patient has received oral metronomic cyclophosphamide with a long-lasting clinical response and improved performance status. Oral metronomic cyclophosphamide is a promising treatment for elderly and frailty advanced ovarian cancer patients and should be further investigated.
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Case Reports Source Type: research
ConclusionPremenopausal Asian women with breast cancer have unique disease characteristics and may benefit from treatment that differs somewhat from international guidelines. Given the great diversity of patients and clinical settings worldwide, the ABCCG advocates evidence-based yet flexible and individualized use of all potential options to improve breast cancer outcomes.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Authors: Ferraro E, Trapani D, Marrucci E, Curigliano G Abstract Introduction: Triptorelin is a luteinizing hormone-releasing hormone analog (LH-RHa) inducing ovarian function suppression (OFS). It is approved by FDA and EMA in association with tamoxifen or aromatase inhibitor (AI) and with fulvestrant and palbociclib in premenopausal women with hormone receptor (HR)-positive breast cancer. Its potential role to preserve ovarian function during chemotherapy has also been recently clarified. Areas covered: Several studies have investigated the role of adding OFS to tamoxifen and aromatase inhibitors as adjuvant trea...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
CONCLUSIONS: Use of non-platinum chemotherapy and even targeted therapy to prolong PFI in patients with EOC recurring between 6 and 12 months leads to worse survival. PMID: 31522837 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
Hall Karteris Ovarian cancer is fifth in the rankings of cancer deaths among women, and accounts for more deaths than any other gynecological malignancy. Despite some improvement in overall-(OS) and progression-free survival (PFS) following surgery and first-line chemotherapy, there is a need for development of novel and more effective therapeutic strategies. In this mini review, we provide a summary of the current landscape of the clinical use of tyrosine kinase inhibitors (TKIs) and mechanistic target of rapamycin (mTOR) inhibitors in ovarian cancer. Emerging data from phase I and II trials reveals that a comb...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | China Health | Complementary Medicine | Herbs | Ovarian Cancer | Ovaries | Study